Preface T | ahe mission of the American Heart Association (AHA) is to reduce premature morbidity and mortality from cardiovascular disease and stroke. The rapid and dramatic advancements of medical science occurring during recent years in drugs, technology, and methods of treatment could conceivably deter the AHA from adequately pursuing its mission, which is based on primary prevention. Recognizing this situation, the AHA, at the urging of its president (1986) (1987) , Howard Morgan, MD, convened a group of science volunteers, who recommended that the AHA plan a series of scientific conferences on prevention. Cholesterol was selected as the first conference topic because of the timeliness of the subject. Future conferences on hypertension, smoking, and possibly other risk factors are planned.
In some respects, the origin of this conference may be traced to the foresight of an AHA committee of science volunteers chaired by Irvine Page in the mid-1950s. In a report made to the AHA, the American Society for the Study of Arteriosclerosis and the AHA Nutrition Committee summarized epidemiologic, experimental, and clinical evidence and concluded that an individual's nutritional pattern is likely an environmental factor in the etiology of atherosclerosis. However, the group also stated that there was no incontrovertible evidence for such a relation. Type of fat and total fat content of the diet emerged as important factors.
This early report set a precedent. Its release received widespread media coverage, and the AHA planted the seeds of cholesterol awareness in the public's mind. In 1961, an ad hoc committee of the AHA prepared an updated report on the possible relation of dietary fat to heart attacks and stroke, which concluded: 1) Overweight persons should decrease their caloric intake and attempt to achieve a desirable body weight. 2) The composition of the diet should be altered by reducing intakes of total fats, saturated fats, and cholesterol and by increasing intakes of polyunsaturated fats. 3) Weight reduction should be facilitated by regular moderate exercise. 4) Men at increased risk for coronary heart disease should pay particular attention to dietary alteration. 5) For those at high risk, dietary changes should be carried out with medical supervision.
Since 1961, the AHA has continually reviewed new data about the relation between diet and coronary heart disease, updating its dietary guidelines in 1965, 1968, 1973, 1978, 1986, and 1988 . Each report has resulted in new and vital AHA public and professional education programs that serve as the practical applications of current research on dietary fat and cholesterol. Because there is a proliferation of this new information, a group of the world's leading experts on cholesterol and lipids convened on August 24-26, 1988, in Washington, DC. Current and emerging data were presented on 1) lipoproteins and the pathogenesis of atherosclerosis; 2) genetic susceptibility to atherosclerosis; 3) basis for dietary treatment; 4) diagnosis, evaluation, and treatment; 5) intervention studies; and 6) drug therapy.
In-depth discussions in each of six designated workshops led to the formulation of recommendations that were subsequently presented to the AHA and other policy-making bodies. The recommendations include professional and public education programs, issues for discussion at scientific conferences, and, most importantly, questions to be developed as research initiatives.
The first prevention conference set a "cholesterol" agenda for at least the next 5 years and, in many ways, should have an impact beyond that time.
ANTONIO M. GoTTo JR., MD, DPHIL Past President American Heart Association Summary The American Heart Association's (AHA's) Prevention Conference I-Cholesterol brought together many of the world's leading lipids experts to discuss current and emerging data in six areas: 1) lipoproteins and the pathogenesis of atherosclerosis; 2) genetic susceptibility to atherosclerosis; 3) scientific basis for dietary treatment; 4) diagnosis, evaluation, and treatment: current status and issues; 5) intervention studies; and 6) drug therapy. The participants were asked to make recommendations to the AHA and other policy-making bodies about long-term needs in each area.
Several recommendations were made for research initiatives related to high density lipoproteins (HDL), stemming from fragmentary knowledge of the functions of HDL in plasma. The biochemical basis for the statistical relation between HDL and atherosclerosis remains unknown.
Interest was expressed in seeking more predictive markers of individual coronary risk and understanding the interactions of lipoproteins with other risk factors such as hypertension and smoking. Epidemiologists were advised to incorporate new biologic data into their data bases and to test these data against established risk factors. Mechanisms contributing to the atherogenicity of lipoproteins in the artery wall need to be elucidated, and animal models are needed for the study of lipoprotein physiology and atherogenesis.
The issue of the potential atherogenicity of triglyceride-rich lipoproteins must also be resolved.
The participants agreed that identification of genetically susceptible individuals would contribute to current population and high-risk strategies in the prevention of atherosclerosis. They recommended several research areas for the identification of new genetic markers, including investigation of the structure and function of candidate genes involved in potentially atherogenic events, the study of families with susceptibility to atherosclerosis and evaluation of the role of these genes by linkage analysis, and the use of mouse genetics to better understand the complex genetic regulation of atherosclerosis susceptibility.
Despite the fact that dietary therapy is the first logical step of treatment, its efficacy has not been proven. The panel recommended further study of the effectiveness of diet for treatment of hyperlipidemia; the effects of dietary composition on lipoprotein metabolism, nutrition, and HDL metabolism; nutrition and thrombogenesis; nutrition and obesity; lipoprotein responsiveness to diet; and nutrition in special groups.
Growing interest in public screening for cholesterol led the panel to make recommendations to physicians about selection of a reliable laboratory for lipid and lipoprotein measurements and desktop analyzers. The need for more sensitive clinical laboratory measurement of triglycerides and HDL cholesterol was cited.
Satisfied that the evidence for intervening to lower elevated low density lipoprotein (LDL) cholesterol in middle-aged men is quite convincing, the panel noted that further clinical trials are needed to extend the applicability of the LDL hypothesis to other segments of the population. A trial testing the benefit of raising low HDL cholesterol levels bears consideration.
Development of noninvasive measures of atherosclerosis and the improvement of invasive techniques were viewed as a high priority.
Finally, physicians need more data on the efficacy of different drugs in the treatment of specific forms of hyperlipoproteinemia. Additional research is needed to evaluate the effectiveness of the reduction of cholesterol in other lipoprotein classes on the risk for coronary heart disease. Diet-drug interaction studies are needed for each class of drugs. The effects of various drugs on growth and development must be assessed. The safety and efficacy of drug combinations need more adequate study. Genetic determinants of drug response must be identified. New drug classes must be developed. Drugs should be better tolerated by patients, and their actions should be limited to specific components of the lipoprotein system.
In addition to research initiatives, many suggestions were made for professional and public education. Prevention of cholesterol elevations through diet and lifestyle modifications should be vigorously pursued. A family-unit approach is recommended. Educational programs should be designed to enhance physician-scientists' understanding of the fundamental principles of experimental research. An annual seminar on clinical trials and cardiovascular disease was suggested. Physicians should receive education about the use of drugs in lipoprotein disorders other than elevated LDL cholesterol.
In public education, special efforts are needed to provide risk-factor education to all socioeconomic and age groups.
The remaining challenge is to prioritize these recommendations, permitting pursuit of an effective long-range plan.
